Edwards Lifesciences Corporation (EWL)
XETR
77.46
+0.44 (+0.57%)
Closed
Aug 24, 2026
Day's Range
75.8477.46
52 wk Range
62.0084.00
Financial Statements - EWL - Edwards Lifesciences Corporation
Revenue
6.06B▲ 31.8%
Net Income
1.06B▼ 69.7%Net Margin 17.6%
EBITDA
1.96B▲ 31.7%
Free Cash Flow
1.33B▲ 507.1%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 6.06B | 4.60B | 6B | 5.38B | 5.23B | 4.38B |
| Cost of Goods | 1.33B | 945.53M | 1.37B | 1.08B | 1.24B | 1.08B |
| Gross Profit | 4.73B | 3.65B | 4.62B | 4.30B | 3.98B | 3.30B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 1.63B | 1.25B | 1.72B | 1.78B | 1.58B | 1.31B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | -511.70M | -27.49M | -180.10M | -38.10M | 116.20M | -407.50M |
| Pre Tax Income | 1.27B | 1.30B | 1.59B | 1.76B | 1.70B | 916.70M |
| Income Tax | 216.90M | 128.69M | 198.70M | 245.50M | 198.90M | 93.30M |
| Net Income | 1.06B | 3.52B | 1.39B | 1.52B | 1.50B | 823.40M |
| EPS Basic | 1.84 | 6.98 | 2.31 | 2.46 | 2.41 | 1.32 |
| EPS Diluted | 1.83 | 6.97 | 2.3 | 2.44 | 2.38 | 1.3 |
| Basic Shares Outstanding | 584.80M | 505.72M | 631.75M | 648.95M | 653.46M | 652.72M |
| Diluted Shares Outstanding | 584.80M | 505.72M | 631.75M | 648.95M | 653.46M | 652.72M |
| Ebit | 1.29B | 1.32B | 1.61B | 1.78B | 1.72B | 932.50M |
| Ebitda | 1.96B | 1.49B | 1.94B | 1.96B | 1.74B | 1.44B |
| Net Income Continuous Operations | 1.06B | 3.52B | 1.39B | 1.52B | 1.50B | 823.40M |
| Minority Interests | 4.10M | 4.90M | 3M | 0 | 0 | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
